FDA Regulatory Writing & Strategy for a Top-20 Global Pharmaceutical Company

Context

A major global pharmaceutical corporation required critical regulatory documentation for a complex drug-related approval pipeline, with high expectations for clarity and traceability.

Overview

Assisted the client’s regulatory affairs organisation in preparing documentation and plans tailored to applicable FDA documentation expectations for the engagement.

Approach

1. Map procedure context and documentation needs with RA stakeholders
2. Author and structure the regulatory plan end-to-end for the client’s use
3. Support documentation practices consistent with electronic records expectations under 21 CFR Part 11 where applicable
4. Iterate with the client’s regulatory affairs team through to a submission-ready package

What we did

• Prepared the regulatory plan from initial framing through a complete, structured package for the client
• Collaborated on clarity and traceability across source materials
• Remained a documentation and strategy support partner — not FDA and not the sponsor of record

Result

We prepared the plan from start to finish. The client submitted it to the U.S. Food and Drug Administration (FDA), and the plan was approved by the FDA. The client remained the party of record. This describes FDA acceptance of that plan — not FDA clearance or approval of a marketed product, and not a partnership with FDA.

Boundaries

• No partnership with FDA; we are not the agency and do not speak for it
• Client owned the submission and agency interactions
• Outcome stated for this anonymised engagement’s plan only — not a guarantee of future FDA decisions
• Published only in anonymised form

Related

Regulatory support · Biotech & pharma · How we work